← 프로그램 목록
Phase 2Active

High-dose methylprednisolone

KiteA Gilead Company

비교

High-dose methylprednisolone(Kite, A Gilead Company)은 FRα 표적 치료제로, Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced 3M syndrome: a case report. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 88% (ClinicalTrials.gov NCT00057811). 차별점: unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 13일 (1일 전)PK/독성 2026년 7월 13일 (1일 전)

FRα

Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma

Active

Technology

humanized anti-programmed death 1 (PD-1) monoclonal antibody, is widely used in the management of advanced ca

unique immune-related adverse events (irAEs) affecting systemic systems and organs, posing a significant challenge in clinical

Mechanism of Action

checkpoint inhibitor-induced 3M syndrome: a case report

immune-mediated necrotizing inflammatory myopathy

apoptosis of CD3/CD28-stimulated Jurkat cells, prioritizing this axis for future mechanistic testing without proving causality in

biomarkers and creatine kinase, alongside neuromuscular involvement, confirmed the clinical diagnosis of ICI-

downregulation

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 60건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2 · Phase 2
  • Status: Recruiting · Completed · Active, not recruiting
  • 주요 endpoint: Community-acquired pneumonia: All-cause mortality (with subsidiary analyses of cause of death and of death at various timepoints following discharge) · Influenza co-primary outcome: All-cause mortality (with subsidiary analysis of cause of death and death at various timepoints following discharge) · Influenza co-primary outcome: Time to discharge alive from hospital · Community-acquired pneumonia: Duration of hospital stay · Community-acquired pneumonia: Composite endpoint of death or need for mechanical ventilation or ECMO
  • 등록된 결과: ORR 88%
  • 핵심: Phase II trial to study the effectiveness of combining rituximab and rasburicase with combination chemotherapy in treati…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

High-dose methylprednisolone은 어떤 치료제인가요?
High-dose methylprednisolone(Kite, A Gilead Company)은 FRα 표적 항체로, Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
High-dose methylprednisolone의 임상 단계는?
High-dose methylprednisolone의 현재 단계는 Phase 2입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.